Article wrongly implied safety of GcMaf
I AM writing to express my concern in relation to your article 'GcMaf supporters want investigation time limit' (11 March).
This article is misleading and implies that these products are safe and fit for use. However our investigation suggests that these products may pose a significant risk to people's health. I fully understand the concerns of people who have serious illnesses and would therefore encourage them to seek advice from their doctor to ensure they receive the most appropriate treatment.
GcMaf products labelled as 'First Immune' were not only manufactured in unacceptable conditions at this specific facility but the originating material was not suitable for human use.
As a result of this we cannot be sure that the product is not contaminated.
People should not start treatment with these specific products.
GcMaf products labelled as 'First Immune' are not licensed medicines and have not undergone approved trials to ensure their quality, safety or effectiveness. It is vitally important that patients currently taking these products seek their doctor's advice as soon as possible. People should continue taking prescribed medicines and follow the advice of their doctor. Our investigations are continuing and in everything we do we are committed to protecting public health.
GERALD HEDDELL,
Director, Inspection, Enforcement and Standards Division, MHRA,
151, Buckingham Palace Road,
London, SW1W 9SZ,
0203 080 7651.
